Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
May 23, 2022 07:29 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a...
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022 06:00 ET
|
Fennec Pharmaceuticals Inc.
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of...
Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™
April 27, 2022 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and...
Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference
March 25, 2022 07:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark™
March 24, 2022 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New...
Fennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update
February 28, 2022 06:00 ET
|
Fennec Pharmaceuticals Inc.
~ Resubmission of NDA for PEDMARK™ Targeted for the First Quarter of 2022 ~ ~ Company has Approximately $21.1 Million in Cash and $5 Million of Funded Debt ~ RESEARCH TRIANGLE PARK, N.C.,...
Fennec Pharmaceuticals Announces Management Change
January 31, 2022 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a...
Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
November 30, 2021 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on...
Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors
November 29, 2021 06:00 ET
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it expects to receive a Complete Response Letter...
Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 06:00 ET
|
Fennec Pharmaceuticals Inc.
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ If Approved by the FDA, PEDMARK™ Stands to Be the First Therapy for the Prevention of Cisplatin-Induced...